Table 1 Baseline patient characteristics
Parameter | N = 27 |
|---|---|
Age (years), mean (SD) | 49.8 (12.7) |
Women, n (%) | 14 (51.9) |
BMI, mean (SD) | 28.4 (5.9) |
Smoking, n (%) | |
Non-smoker | 19 (70.4) |
Former smoker | 8 (29.6) |
Age at diagnosis (years), mean (SD)a | 30.2 (12.2) |
Time since diagnosis (years), mean (SD) | 19.2 (13.8) |
Asthma phenotype, n (%) | |
Eosinophilic | 24 (88.9) |
Eosinophilic and atopic | 3 (11.1) |
Pre-BD FEV1, mean (SD)b | |
mL | 1,813.3 (480.8) |
% | 62.1 (14.6) |
Post-BD FEV1, mean (SD)b | |
mL | 1,989.3 (819.7) |
% | 65.7 (20.5) |
ACTc | |
Mean (SD) | 14 (6.1) |
Controlled asthma (ACT ≥ 20), n (%) | 6 (22.2) |
miniAQLQ, mean (SD) | 3.4 (0.7) |
FeNO (ppb), Mean (SD)d | 76.2 (56.5) |
Blood eosinophil count (cells/μL), mean (SD)a | 371.9 (315.5) |
< 300 cells/μL, n (%) | 11 (40.7) |
≥ 300 cells/μL, n (%) | 15 (55.6) |
Total IgE (IU/ml), mean (SD)b | 593.1 (1,054.5) |
Asthma-treatment in the previous year, n (%) | |
ICS + LABA | 27 (100) |
OCS | 24 (88.9) |
LAMA | 22 (81.5) |
LTRA | 17 (63) |
ICS | 8 (29.6) |
Macrolides | 6 (22.2) |
Theophylline | 1 (3.7) |
LABA | 1 (3.7) |
Biologic agent | |
Mepolizumab (anti-IL5) | 23 (85.2) |
Reslizumab (anti-IL5) | 2 (7.4) |
Omalizumab (anti-IgE) (first line)/Mepolizumab (second line) | 1 (3.7) |
Omalizumab (first line)/Reslizumab (second line) | 1 (3.7) |
Oral prednisone dose (mg/day), mean (SD) | 20.3 (20.1) |
Inhaled budesonide (in combination) dose (μg/ day), Mean (SD) | 305 (60.2) |
Duration of prior biologic therapy (days), mean (SD) | |
Duration of prior mepolizumab therapya | 250.8 (167.6) |
Duration of prior reslizumab therapy | 150.7 (58.4) |
Duration of prior omalizumab therapy | 77 (107.5) |
Time since prior biologic therapy (days), mean (SD)a | 121.4 (110.7) |